source
- Argenx to acquire Unnatural Products' macrocyclic peptide platform for $550 million upfrontArgenx announced that it will acquire the California-based protein specialist Unnatural Products, paying $550 million upfront for its macrocyclic peptide platform. The deal could rise to more than…
- FDA requires GLP-1 drug labels to include warning about rare eye diseaseThe FDA has issued a directive to manufacturers of GLP-1 therapies, instructing them to revise product labeling. The label change must highlight an increased risk of a rare ocular condition that c…